Dr. Mriganka Baruah
Medicine Specialist &; Diabetologist,
MBBS, MD (Medicine) Rehed. No13898 (AMC),
Fellowship in Diabetes (CMC, Vellore),
Fellowship in Diabetes (Diabetes india).

The study aimed to assess the effectiveness of sacubitril/valsartan in treating patients with chronic heart failure (CHF) after cardiac valve surgery (CVS). Data was collected from 259 patients who underwent CVS due to valvular heart disease and were admitted to the hospital with CHF from January 2018 to December 2020. The patients were divided into two groups: Group A (treatment with sacubitril/valsartan) and Group B (treatment without sacubitril/valsartan). The study found that Group A had a higher effective rate (82.56% versus 65.52%), improved left ventricular ejection fraction (LVEF), decreased left ventricular end-diastolic/-systolic diameter (LVEDD/LVESD), and decreased the N-terminal prohormone of B-type natriuretic peptide (NT-proBNP). Systolic and diastolic blood pressure decreased more in Group A than in Group B. Hyperkalaemia, angioedema, liver and renal insufficiency, symptomatic hypotension, and acute heart failure had no statistical differences between the two groups.

Click Here to view the article:

Springer Nature